参考文献/References:
[1]Lam SW,Jimenez CR,Boven E.Breast cancer classification by proteomic technologies:Current state of knowledge[J].Cancer Treatment Reviews,2014,40(1):129-138.[2]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[3]Shi Y,Juan J,Wenfei J,et al.Therapeutic landscape in mutational triple negative breast cancer[J].Molecular Cancer,2018,17(1):99.[4]Bianchini G,Balko JM,Mayer IA,et al.Triple-negative breast cancer:challenges and opportunities of a heterogeneous disease[J].Nature Reviews Clinical Oncology,2016,13(11):674-690.[5]Abbed T,Shifrin DA.Aesthetic Female-to-Male Chest Transformation: Power of Combining Modified Mastectomy with a Pectoral Implant[J].Plast and Reconstructive Surgery-Global Open,2017,5(8):e1445.[6]Lehmann BD,Jovanovic B,Chen X,et al.Refinement of Triple-Negative Breast Cancer Molecular Subtypes:Implications for Neoadjuvant Chemotherapy Selection[J].PLoS One,2016,11(6):e0157368.[7]Burstein MD,Tsimelzon A,Poage GM,et al.Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer[J].Clinical Cancer Research,2014,21(7):1688-1698.[8]Bettaieb A,Paul C,Plenchette S,et al.Precision medicine in breast cancer:reality or utopia?[J].Journal of Translational Medcine,2017,15(1):139.[9]Clough KB,Acosta-Marin V,Nos C,et al.Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery:A French National Survey[J].Annals of Surgical Oncology,2015,22(11):3504-3511.[10]Mittendorf EA,Buchholz TA,Tucker SL,et al.Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy[J].Annals of Surgery,2013,257(2):173-179.[11]Masuda H,Baggerly KA,Wang Y,et al.Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J].Clin Cancer Res,2013,19(19):5533-5540.[12]郭春龙,曲世静.三阴性乳腺癌化疗方案的对比[J].中外医疗,2012,31(3):8-9.[13]Cardoso F,Costa A,Norton L,et al.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger[J].Annals of Oncology,2014,25(10):1871-1888.[14]Untch M,Jackisch C,Schneeweiss A,et al.Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69):a randomised,phase 3 trial[J].The Lancet Oncology,2016,17(3):345-356.[15]Sikov WM,Berry DA,Perou CM,et al.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer:CALGB 40603 (Alliance)[J].Journal of Clinical Oncology,2015,33(1):13-21.[16]陈晓越.不同新辅助化疗方案治疗三阴乳腺癌临床对比研究[J].中国地方病防治杂志,2018,33(1):116-117.[17]Tutt A,Ellis P,Kilburn L,et al.Abstract S3-01:The TNT trial:A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)[J].Cancer Research,2015,75(9 Suppl):S3-01-S3-01.[18]Dingle BH,R Bryan R,Brouwers MC.The role of gemcitabine in the treatment ofcholangiocarcinoma and gallbladder cancer:a systematic review[J].Canadian Journal of Gastroenterology,2016,19(12):711-716.[19]Yoshitomi S,Taira N,Doihara H,et al.A phase 1,dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer[J].Cancer Chemotherapy and Pharmacology,2016,78(2):289-294.[20]Minckwitz GV,Loibl S,Schneeweiss A,et al.Abstract S2-04:Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)[J].Cancer Research,2016,76(4 Supplement):S2-04-S2-04. [21]Masuda N,Lee S-J,Ohtani S,et al.Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy[J].New England Journal of Medicine,2017,376(22):2147-2159.[22]Marangoni E,Laurent C,Coussy F,et al.Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers[J].Clin Cancer Res,2018,24(11):2605-2615. [23]Rajabpour A,Afgar A,Mahmoodzadeh H,et al.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells[J].Cancer Chemother Pharmacol,2017,80(4):765-775.[24]Buys SS,Sandbach JF,Gammon A,et al.A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes[J].Cancer,2017,123(10):1721-1730.[25]Neophytou C,Boutsikos P,Papageorgis P.Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis[J].Front Oncol,2018(8):31.[26]Isakoff SJ,Puhalla S,Domchek SM,et al.A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer:design and rationale[J].Future Oncology (London, England),2017,13(4):307-320.[27]Massihnia D,Perez A,Bazan V,et al.A headlight on liquid biopsies: a challenging tool for breast cancer management[J].Tumor Biology,2016,37(4):4263-4273.[28]Kim SB,Dent R,Im SA,et al.Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS):a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J].The Lancet Oncology,2017,18(10):1360-1372.[29]Xu S,Li S,Guo Z,et al.Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models[J].Mol Cancer Ther,2013,12(8):1665-1675.[30]Tomioka N,Azuma M,Ikarashi M,et al.The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)[J].Breast Cancer,2017,25(1):1-9.[31]Akhurst RJ,Hata A.Targeting the TGFbeta signalling pathway in disease[J].Nature Reviews Drug Discovery,2012,11(10):790-811.[32]Wang K,Zhang Q,Li D,et al.PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor[J].Clin Cancer Res,2015,21(6):1487-1496.[33]Balko JM,Giltnane JM,Wang K,et al.Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets[J].Cancer Discov,2014,4(2):232-245.[34]Traina TA,Miller K,Yardley DA,et al.Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer[J].Journal of Clinical Oncology,2018,36(9):JCO2016713495.[35]Ingle JN,Long HJ,Twito DI,et al.Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer[J].An Updated Analysis,1991,67(4):886-891.[36]Seitz S,Buchholz S,Schally A,et al.Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125[J].BMC Cancer,2014,14(1):847.[37]Solans BP,Lopez-Diaz de Cerio A,Elizalde A,et al.Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach[J].British Journal of Clinical Pharmacology,2019,85(8):1670-1683.[38]Emens LA.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade[J].Expert Review of Anticancer Therapy,2012,12(12):1597-1611.[39]Sabado RL,Balan S,Bhardwaj N.Dendritic cell-based immunotherapy[J].Cell Research,2017,27(1):74-95.[40]黄羚,江媚,刘宁远.三阴性乳腺癌患者中医体质类型分析及其与TOP2A基因表达的相关性[J].中国中医药信息杂志,2015(1):19-22.[41]郑巧,崔飞飞.疏肝益肾方加减联合放化疗对三阴乳腺癌患者免疫调控及生活质量的影响[J].中医杂志,2015,56(20):1742-1745.